Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.
News & Analysis: CRISPR Therapeutics
This gene-editing leader's current programs only reveal a hint of what it could become.
These disruptive biotech stocks could prove to be great investments in the long run.
Analysts have been raising their price targets on the stock based on news about a treatment the biotech is developing in partnership with Vertex Pharmaceuticals.
Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.
Innovation might be worth the high risk up front investment.
CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.
Its approach to cell therapy is lucrative and immensely powerful for patients.
These biotechs are fueling up for massive market launches.
The company flipped to a bottom-line loss for the period.